GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (OTCPK:RGTPQ) » Definitions » Shiller PE Ratio

Regenetp (Regenetp) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Regenetp Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenetp Shiller PE Ratio Historical Data

The historical data trend for Regenetp's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Shiller PE Ratio Chart

Regenetp Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenetp Quarterly Data
Apr18 Jul18 Oct18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regenetp's Shiller PE Ratio

For the Biotechnology subindustry, Regenetp's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenetp's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenetp's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regenetp's Shiller PE Ratio falls into.



Regenetp Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regenetp's E10 for the quarter that ended in Mar. 2023 is calculated as:

For example, Regenetp's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.58/127.3478*127.3478
=-0.580

Current CPI (Mar. 2023) = 127.3478.

Regenetp Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201304 -63.000 98.107 -81.777
201307 -94.500 98.557 -122.106
201310 -111.000 98.536 -143.457
201401 -106.500 98.692 -137.423
201404 -84.000 100.023 -106.947
201407 -66.000 100.520 -83.615
201410 -124.500 100.176 -158.270
201501 -36.000 98.604 -46.495
201504 -78.000 99.824 -99.507
201507 -5.500 100.691 -6.956
201510 -10.667 100.346 -13.537
201601 -99.250 99.957 -126.447
201604 -14.500 100.947 -18.292
201607 -23.500 101.524 -29.478
201610 3.500 101.988 4.370
201701 -42.250 102.456 -52.514
201704 -587.500 103.167 -725.199
201707 -23.250 103.278 -28.669
201710 1.500 104.070 1.836
201801 -57.750 104.578 -70.324
201804 -36.750 105.708 -44.273
201807 -21.500 106.324 -25.751
201810 -24.000 106.695 -28.646
201903 -29.500 107.251 -35.028
201906 -23.000 108.070 -27.103
201909 -21.750 108.329 -25.568
201912 -19.000 108.420 -22.317
202003 -9.750 108.902 -11.402
202006 -8.250 108.767 -9.659
202009 -4.500 109.815 -5.218
202012 -6.750 109.897 -7.822
202103 -6.000 111.754 -6.837
202106 -1.010 114.631 -1.122
202109 -0.370 115.734 -0.407
202112 -2.620 117.630 -2.836
202203 -2.370 121.301 -2.488
202206 -0.490 125.017 -0.499
202209 -0.470 125.227 -0.478
202212 -0.130 125.222 -0.132
202303 -0.580 127.348 -0.580

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenetp  (OTCPK:RGTPQ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Regenetp Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Regenetp's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenetp (Regenetp) Business Description

Traded in Other Exchanges
N/A
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.
Executives
Peter A Cohen director 40 WEST 57TH STREET, SUITE 2020, NEW YORK NY 10019
David B Seaburg director 1960 S 4250 W, SALT LAKE CITY UT 84104
Richard Hague officer: Chief Operating Officer 1960 S 4250 W, SALT LAKE CITY UT 84104
Cameron J. Hoyler other: General Counsel 1960 S 4250 W, SALT LAKE CITY UT 84104
Jeffrey Hansen Dyer director 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Jessica Xiaolin Shen director POLARITYTE, INC. (NASDAQ: PTE), 1960 S. 4250 WEST, SALT LAKE CITY UT 84104
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Paul Elliot Mann officer: Chief Financial Officer C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Jacob Alexander Patterson officer: Chief Financial Officer 14822 S. ROSESCAPE CIRCLE, HERRIMAN UT 84096
Denver Lough 10 percent owner, other: Prior D&O within 90 days 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Rainer M Erdtmann director 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Edward Winslow Swanson director, officer: Chief Operating Officer 181 DANTE AVE., TUCKAHOE NY 07070
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Willie C Bogan director 1943, ROSECREST DRIVE, OAKLAND CA 94602